Skip to content

Trial Summary

A Randomised, double-blinded phase II study of gemcitabine and nab‐paclitaxel with CEND‐1 or placebo in patients with untreated metastatic pancreatic ductal adenocarcinoma.



ACTRN/NCT /ethics:


Scientific title:

The ASCEND Study: Gemcitabine and Nab-Paclitaxel With CEND-1 or Placebo in Patients With Untreated Metastatic Pancreatic Ductal Adenocarcinoma (ASCEND)

Sponsor / Cooperative group:

Australasian Gastro-Intestinal Trials Group

Trial & Patient Characteristics

Cancer TypePancreas
Trial TypeTreatment
PhasePhase II
Age Range18 years and older
Tumour Stream -
Cancer StageMetastatic or Widespread
Anticipated Start Date2022-04-13
Anticipated End Date2024-10-01

Participating Hospitals

HospitalThe Queen Elizabeth Hospital
Clinical Trial CoordinatorStella Papacharissiou
Phone08 8222 6410
Principal InvestigatorProfessor Tim Price
Recruitment StatusRecruiting
HospitalFlinders Medical Centre
Clinical Trial CoordinatorAlison Richards
Phone08 8206 4835
Principal InvestigatorDr Chris Karapetis
Recruitment StatusRecruiting